MYLAN/MOVA GENERIC GLYBURIDE NEGOTIATIONS COULD ALLOW MYLAN PRODUCT TO REMAIN ON MARKET; MOVA PREVAILS IN INJUNCTION HEARING TO RESCIND ANDA APPROVAL
Executive Summary
Mylan and Mova are negotiating to allow Mylan to continue to market a generic version of micronized glyburide (Pharmacia & Upjohn's diabetes therapy Glynase) following a federal court opinion in favor of Mova that would rescind Mylan's ANDA approval.